Compare Moderna, Inc. (MRNA) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Quanta Services Inc — how do they compare? Moderna, Inc. trades at $63.99 (market cap $24.18B), while Quanta Services Inc trades at $682.42 (market cap $100.82B). The key difference: Quanta Services Inc is far larger — about 4.2× Moderna, Inc.'s market cap, and Quanta Services Inc pays a 0.07% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PWR | |
|---|---|---|
Market Cap | $24.18B | $100.82B |
Sector | Health | Industrials |
52-Week High | $81.80 | $785.24 |
52-Week Low | $22.36 | $372.50 |
Enterprise Value | $20.33B | $106.91B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
PWR trades at $680.97, up 3.04% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported robust revenue growth, reaching $28.48B in 2025, and raised its 2026 outlook, supported by a record backlog and infrastructure demand. However, valuation ratios like a P/E of 76.73 and P/S of 3.1 are elevated, indicating high expectations.
The outlook is positive due to accelerating infrastructure investments and analyst consensus favoring buys, with a price target of $809.75. Risks include high valuation sensitivity, project execution challenges, and macroeconomic pressures on capital spending. Earnings growth remains the key catalyst for further upside, but investors should weigh premium pricing against execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
